---
title: "Codexis: Neutral Stance Maintained as Execution Risks Offset Solid Q1; $2 Price Target Reaffirmed"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285644115.md"
description: "Codexis maintains a Hold rating with a $2 price target, as analyst Brendan Smith from TD Cowen cites solid Q1 performance offset by execution risks. The company exceeded revenue expectations due to Merck contributions but relies on future partnerships and revenue from its ECO platform. Upcoming milestones, including the TIDES presentation and GMP facility retrofit, are crucial but their impact remains uncertain, justifying the neutral stance."
datetime: "2026-05-08T00:55:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285644115.md)
  - [en](https://longbridge.com/en/news/285644115.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285644115.md)
---

# Codexis: Neutral Stance Maintained as Execution Risks Offset Solid Q1; $2 Price Target Reaffirmed

Codexis, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Brendan Smith from TD Cowen maintained a Hold rating on the stock and has a $2.00 price target.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Brendan Smith has given his Hold rating due to a combination of factors, including Codexis’ solid Q1 performance and the dependence on future execution. The company exceeded revenue expectations largely because of the Merck transfer-related contribution and reaffirmed its long-term targets, but much of the growth story still hinges on securing new CDMO and pharma partnerships and translating its ECO platform into recurring revenue.

While management’s view of a sizable siRNA manufacturing opportunity and the potential differentiation from stereochemical control are encouraging, these remain early-stage validation and commercialization efforts. The upcoming TIDES presentation, planned GMP facility retrofit, and scale-up to half-kilo production are important milestones, yet the timing and magnitude of their impact are uncertain, supporting a neutral stance and an unchanged $2 price target.

### Related Stocks

- [CDXS.US](https://longbridge.com/en/quote/CDXS.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [Allworth Financial LP Grows Stake in Merck & Co., Inc. $MRK](https://longbridge.com/en/news/286522605.md)
- [Erasca Merck Pact Puts ERAS 0015 KEYTRUDA Combo In Investor Focus](https://longbridge.com/en/news/287222028.md)
- [Merck ADC, licensed from China, hits mark in first big global trial](https://longbridge.com/en/news/287075287.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)